Sun Pharma Zooms 10% as June Quarter Earnings Beat Estimates

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks


Login Failure
(Please do not use this option on a public machine)
  Sign Up | Forgot Password?  
  • Home
  • Views On News
  • Jul 30, 2021 - Sun Pharma Zooms 10% as June Quarter Earnings Beat Estimates

Sun Pharma Zooms 10% as June Quarter Earnings Beat Estimates

Jul 30, 2021

Sun Pharma share price rose over 10% today to a 52-week high of Rs 780 on the BSE, after the company reported strong results for the June quarter.

Its bottomline surged 73% year on year (YoY) to Rs 19.8 bn. The reported net profit in the same quarter stood at Rs 14.4 bn.

Strong operational performance

Sun Pharma was able to post good set of numbers mainly due to its robust operational performance.

The company reported consolidated sales of Rs 96.7 bn, a growth of 29% over last year. If compared sequentially, sales were up 14%.

Topline figures beat estimates as the street was expecting Sun Pharma to post a 19.5% revenue growth for the quarter.

The growth in revenues was due to 39% YoY jump in domestic formulations to Rs 33.1 bn. It can also be attributed to the 35% YoY rise in US formations business to Rs 28 bn.

--- Advertisement ---
The Hidden Opportunity in EV Stocks No One Knows About

With today's fast-changing technology and concern about the environment, the popularity of electric vehicles (EVs) has been on the rise.

Most investors go the usual route of investing in large companies and waiting to rake in profits.

We believe that's not the best approach.

In fact, our research has uncovered a hidden way to make potentially windfall gains from this EV opportunity.

Interested to know more? You can get all details by clicking the link below:

Equitymaster's Latest Research Project - Details

The topline base for the year-ago quarter was also low, which was affected by the national lockdown in India and reduced sales in major export markets.

EBITDA jumped 59% YoY to Rs 27.7 bn.

Sun Pharma spent more towards its R&D amounting to Rs 5.9 bn, a jump of 41% from the year-ago quarter.

In a press release, Sun Pharma's MD Dilip Shanghvi said,

  • We witnessed a strong Q1, driven by a combination of robust core business growth, low base and some sales of Covid products. We are enthused by the all-round growth across all our businesses compared to Q4 last year.

During the quarter, Sun Pharma repaid debt of about US$185 m. Over the last five quarters, the company has repaid debt of about US$765 m.

Business segments

Sun Pharma is ranked as the top company and holds above 8% market share in the Indian pharma market as per AIOCD AWACS MAT June-2021 report.

For the June quarter under review, the company launched 13 new products in the Indian market.

Sale of branded formulations in India were reported at Rs 33,084 m, up 39% YoY. US sales accounted for 29% of the total consolidated sales and rose 35% YoY.

Its emerging market sales were at US$218 m, a growth of 25% YoY. Meanwhile, Sun Pharma's external sales of API were down 7% YoY.

FREE Event: Discover Your First Stock for a Potential Rs 7 Crore in Long-term Wealth

Relieved by the lawsuit

During the quarter, the company reported a one-time exceptional loss of Rs 6.3 bn in relation to payments made for settlement of antitrust litigations.

For this, the drugmaker has already made provisions of Rs 4.4 bn.

Further, the company took charge of Rs 1.5 bn during the quarter for impairment of acquired intangible assets under development and Rs 0.4 bn write down of assets.

Note that this settlement is a major relief for the company and its subsidiary as it remained an overhang on earnings given that it could have led to criminal and civil action against the company if found guilty in the US courts.

Equitymaster on the pharma sector

We reached out to Tanushree Banerjee, Co-Head of Research at Equitymaster, and editor of the premium stock recommendation service StockSelect, for her view on the pharma sector.

Here's what she has to say...

  • The second Covid wave has given a new lease of life to pharma stocks. As the sector continues to invest in capacities for new drugs, the profitability will depend on the companies' ability to seek USFDA approval for the plants.

    Or their ability to tie up with MNC pharma for producing variants of their vaccine.

--- Advertisement ---
What CNBC Won't Tell You...

The next 10 years would be a golden period for Indian investors...

The "Big Bull" Rakesh Jhunjhunwala claims it could be one of the largest stock market bull runs in India ever...

And veteran investor Raamdeo Agarwal says the S&P BSE Sensex could even reach 200,000 points in the next 10 years... All thanks to these...

Highly Powerful Wealth-Building Mega-Trends

How the markets reacted to Sun Pharma's earnings

Sun Pharma share price opened the day on a flat note at Rs 704 compared to its previous close of Rs 703.25.

Just after the company announced its results during market hours, its shares saw a spike and rose over 10% to a new 52-week high.

Over the past year, Sun Pharma shares have gained 38%.

At the current price of Rs 774, the company commands a marketcap of Rs 1,857 bn.

About Sun Pharma

Sun Pharma including its subsidiaries and associates is the fourth largest global specialty generic company that is ranked 1st in India and 8th in the US.

It's the largest Indian pharmaceutical company in the US and among the leading Indian pharmaceutical companies in emerging markets.

The company manufactures and markets a large basket of pharmaceutical formulations covering a broad spectrum of chronic and acute therapies.

It includes generics branded generics complex or difficult to make technology intensive products over-the-counter (OTC) products anti-retrovirals (ARVs) Active Pharmaceutical Ingredients (APIs) and intermediates.

To know more about the company, check out Sun Pharma company fact sheet and quarterly results.

For a sector overview, read our pharmaceuticals sector report.

You can also compare Sun Pharma with its peers.

Sun Pharma vs Lupin

Sun Pharma vs Alembic Pharma

Sun Pharma vs Natco Pharma

To know what's moving the Indian stock markets today, check out the most recent share market updates here.

Disclaimer: This article is for information purposes only. It is not a stock recommendation and should not be treated as such. Learn more about our recommendation services here...

Equitymaster requests your view! Post a comment on "Sun Pharma Zooms 10% as June Quarter Earnings Beat Estimates". Click here!


More Views on News

SUN PHARMA 2020-21 Annual Report Analysis (Annual Result Update)

Oct 22, 2021 | Updated on Oct 22, 2021

Here's an analysis of the annual report of SUN PHARMA for 2020-21. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

Sun Pharma's Stock Falls 4% After Its March Quarter Results (Views On News)

May 28, 2021

In the past three months, the stock has outperformed the market by gaining nearly 20%. Can it go higher?

What's Behind the Rally in Pharma Stocks? (Views On News)

May 11, 2021

The second wave of Covid has given a new lease of life to pharma stocks.

3 Indian Pharma Companies that are Investing Big Time for the Future (Views On News)

Nov 9, 2021

In 2021, R&D of pharma companies roared to life in a never-before-seen way.

5 Stocks to Watch Out for Amid the Omicron Outbreak (Views On News)

Dec 3, 2021

As the new variant of Covid-19 emerges, keep an eye on these stocks.

More Views on News

Most Popular

Infosys vs TCS: Which is Better? (Views On News)

Nov 26, 2021

In the post pandemic era, the top two IT companies in India are fighting to capture the growing demand for IT.

This Multibagger Stock Zooms 20% After Dolly Khanna Buys Stake (Views On News)

Nov 24, 2021

Shares of this edible oil company zoomed over 50% in three days after ace investor bought around 1% stake.

6 Popular Stocks that Turned into Penny Stocks (Views On News)

Nov 27, 2021

A look at popular stocks that crashed big time and never recovered, i.e. which went from 'Multibaggers to Multibeggers'.

5 Indian Companies Embracing Blockchain Technology (Views On News)

Nov 23, 2021

Blockchain adoption in India was slow in the past. Now, the technology is being well received.

India's Top 5 Monopoly Stocks to Watch Out for (Views On News)

Nov 30, 2021

These 5 companies dominate their sectors with a huge piece of the pie.


Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms


Dec 3, 2021 (Close)


  • Track your investment in SUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks